-
1.发明授权ENTERICALLY TRANSMITTED NON-A/NON-B HEPATITIS VIRAL AGENT AND CHARACTERISTIC EPITOPES THEREOF 失效肠溶传输非A /非B型肝炎病毒剂与表位SELBIGEM签名
公开(公告)号：EP0476130B1
公开(公告)日：2008-07-09
申请号：EP91908163.8
申请日：1991-04-05
申请人： GENELABS TECHNOLOGIES, INC. , GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS
发明人： REYES, Gregory, R. , YARBOUGH, Patrice, O. , BRADLEY, Daniel, W. , KRAWCZYNSKI, Krzysztof, Z. , TAM, Albert , FRY, Kirk, E.
CPC分类号： C07K16/10 , A61K38/00 , A61K39/00 , C07K14/005 , C07K2319/00 , C07K2319/40 , C07K2319/61 , C12N2770/24222
-
2.发明授权COMBINATION OF DHEA AND CALCITONIN FOR THE TREATMENT OF SUBNORMAL BONE MINERAL DENSITY 有权DHEA和降钙素的骨密度低于正常的处理组合物
公开(公告)号：EP1231983B1
公开(公告)日：2006-05-17
申请号：EP00978330.9
申请日：2000-11-13
IPC分类号： A61P19/10 , A61K38/22 , A61K38/23 , A61K31/66 , A61K31/565
CPC分类号： A61K38/22 , A61K31/5685 , A61K38/225 , A61K38/23 , Y10S514/808 , A61K2300/00
摘要： A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e.g., for treatment of systemic lupus erythematosus (SLE).
-
3.发明公开NITROGEN-CONTAINING HETEROARYL DERIVATIVES FOR THE TREATMENT OF HCV-INFECTION 审中-公开含氮HETEROARYLDERIVATIVE丙型肝炎病毒感染的治疗
公开(公告)号：EP1631554A2
公开(公告)日：2006-03-08
申请号：EP04776308.1
申请日：2004-06-04
IPC分类号： C07D235/18 , C07D403/12 , A61K31/4184 , A61P31/12
CPC分类号： C07D235/18 , C07D401/14 , C07D403/12
摘要： Disclosed are compounds of formula (I), compositions and methods for treating Flaviviridae family virus infections.
-
4.发明授权
公开(公告)号：EP0682703B1
公开(公告)日：2004-05-19
申请号：EP94907948.7
申请日：1994-02-02
IPC分类号： C12N15/12 , C12N15/62 , G01N33/566 , G01N33/577 , C12P21/08 , A61K39/21
CPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , C07K14/005 , C07K16/1036 , C07K2319/00 , C07K2319/40 , C12N2740/14022
摘要： Novel HTLV-I and HTLV-II peptides are disclosed for use in diagnostic assays for detecting and confirming HTLV-I and HTLV-II infection in human sera. The peptides are derived from analogous regions of HTLV-I and HTLV-II gp21 envelope protein, and are diagnostic of HTLV-I or HTLV-II infection. The invention also includes an assay kit and method for detecting, and discriminating between, HTLV-I and HTLV-II infection in humans.
-
5.发明公开TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WITH DEHYDROEPIANDROSTERONE 审中-公开治疗系统性红斑狼疮（SLE）与脱氢表雄酮
公开(公告)号：EP1231924A2
公开(公告)日：2002-08-21
申请号：EP00980257.0
申请日：2000-11-13
IPC分类号： A61K31/5685 , A61P37/00 , A61P5/26
CPC分类号： A61K31/5685 , A61K45/06 , A61K2300/00
摘要： This invention provides a method of treating systemic lupus erythematosus (SLE) with (DHEA) and a related pharmaceutical product.
-
公开(公告)号：EP0763114B1
公开(公告)日：2001-12-05
申请号：EP95922085.6
申请日：1995-05-19
CPC分类号： C07K14/005 , A61K38/00 , C12N2770/24222
摘要： Polypeptide antigens are disclosed which are immunoreactive with sera from individuals having a non-A, non-B, non-C, non-D, non-E Hepatitis, herein designated Hepatitis G virus (HGV). Corresponding genomic-fragment clones containing polynucleotides encoding the open reading frame sequences for the antigenic polypeptides are taught. The antigens are useful in diagnostic methods for detecting the presence of HGV in test subjects. The antigens are also useful in vaccine and antibody preparations. In addition, the entire coding sequences of two HGV isolates are disclosed. Methods are presented for nucleic acid-based detection of HGV in samples and also methods for the isolation of further genomic sequences corresponding to HGV.
-
公开(公告)号：EP0684999A1
公开(公告)日：1995-12-06
申请号：EP94907769.0
申请日：1993-12-20
发明人： EDWARDS, Cynthia, A. , CANTOR, Charles, R. , ANDREWS, Beth, M. , TURIN, Lisa, M. , FRY, Kirk, E.
CPC分类号： C12Q1/6811 , C07K14/47 , C12N15/1048 , C12N15/67 , C12Q1/6883 , C12Q1/705 , C12Q2525/131 , C12Q2525/161
摘要： The present invention defines a DNA protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein-binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.
-
公开(公告)号：EP0593618A1
公开(公告)日：1994-04-27
申请号：EP92915116.0
申请日：1992-06-26
CPC分类号： C12N15/67 , C07K14/47 , C12N15/1048 , C12Q1/6811 , C12Q1/6883 , C12Q1/705 , C12Q2525/161 , C12Q2525/131
摘要： La présente invention définit une méthode utile pour le tri de banques de données de composés synthétiques ou biologiques en fonction de leur capacité à lier les séquences de test d'ADN spécifiques. La méthode est aussi utile pour déterminer la spécificité de séquence et l'affinité relative à la liaison d'ADN de molécules de liaison d'ADN pour toute séquence d'ADN particulière. La méthode fait intervenir une compétition dans laquelle la liaison d'une molécule de test avec une séquence de test d'ADN modifie les caractéristiques de liaison d'une protéine de liaison d'ADN avec sa séquence de liaison. Lorsqu'une telle molécule de test se lie avec la séquence de test, l'équilibre des complexes ADN-protéine est dérangé, provoquant des changements dans le rapport entre l'ADN non lié et les complexes ADN-protéine. Le test est versatile dans le fait que toute séquence de test peut être testée en plaçant la séquence de test à côté d'une protéine définie liant la séquence de tri de l'ADN.
-
公开(公告)号：EP0569479A1
公开(公告)日：1993-11-18
申请号：EP92904689.0
申请日：1992-01-21
发明人： HWANG, Kou, M. , QI, You, M. , LIU, Su-Ying , LEE, Thomas, C. , CHOY, William , CHEN, Jen
CPC分类号： C07C59/52 , A61K31/18 , A61K31/185 , A61K31/19 , A61K31/215 , A61K31/255 , A61K31/66 , A61K31/765 , A61K31/795 , A61K31/80 , C07C65/105 , C07C309/11 , C07C309/24 , C07C309/42 , C07C309/43 , C07C309/44 , C07C309/50 , C07C309/58 , C07C309/60 , C07C309/73 , C07C309/77 , C07C311/29 , C07C311/37 , C07C311/48 , C07C317/22 , C07C323/21 , C07F9/3834 , C07F9/3882
摘要： Composition pharmaceutique destinée à être utilisée pour inhiber la coagulation sanguine chez un patient. Cette composition comprend un composé macrocyclique constitué de sous-unités de structures cycliques aryle reliées les unes aux autres par des liaisons à pont fixées sur les structures cycliques et renfermant des substituants provenant d'acide sulfonique fixés sur des atomes ne servant pas de pont des sous-unités, qui sont incorporées dans un support pharmaceutical acceptable. Cette invention concerne également de nouveaux composés macrocycliques.
-
10.发明公开Ppharmaceutical compositions coprising polymorphic forms of dehydroepiandrosterone 审中-公开脱氧核糖核酸die ten ten ten ten ten ten ten ten ten ten ten ten ten ten ten ten ten
公开(公告)号：EP2233141A1
公开(公告)日：2010-09-29
申请号：EP09173572.0
申请日：2000-03-16
IPC分类号： A61K31/5685 , A61P19/10 , A61P37/00 , A61P21/00
CPC分类号： A61K31/5685
摘要： Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms, for therapeutic applications. In one embodiment, the formulation comprises, in solid form, DHEA, at least 85% of which is present as a single polymorph selected from the form I polymorph or the form II polymorph, and at least one pharmaceutical excipient. Methods for making and using such compositions are also disclosed.
摘要翻译： 公开了包含用于治疗应用的富含选定多态形式的脱氢表雄酮（DHEA）的改进的药物制剂。 在一个实施方案中，制剂以固体形式包含DHEA，其中至少85％作为选自I型多晶型物或II型多晶型物的单一多晶型物和至少一种药物赋形剂存在。 还公开了制备和使用这些组合物的方法。
-
-
-
-
-
-
-
-
-
搜索结果
58 条记录 (耗时 0.043 秒)
